--- license: cc-by-4.0 task_categories: - tabular-classification language: - en tags: - substandard-falsified-medicines - tuberculosis - anti-TB - rifampicin - MDR-TB - DOTS - synthetic - sub-saharan-africa pretty_name: Anti-TB Medicine Quality (SSA) size_categories: - 10K ⚠️ **Synthetic dataset** — Parameterized from published SSA literature, not real observations. Not suitable for empirical analysis or policy inference. # Anti-TB Medicine Quality in Sub-Saharan Africa ## Abstract Synthetic dataset modelling anti-TB medicine quality, rifampicin degradation, treatment outcomes, and MDR-TB emergence across DOTS programs, MDR-TB units, and informal markets in SSA. ~70% of quality reports detected falsified/substandard TB medicines; substandard rifampicin drives treatment failure and MDR-TB. ## Parameterization Evidence | Parameter | Value | Source | Year | | --- | --- | --- | --- | | ~70% reports detected SF TB/HIV medicines | Prevalence | IntechOpen | 2024 | | Rifampicin most commonly SF anti-TB drug | Quality | WHO/Lancet ID | 2020 | | SF rifampicin → treatment failure, MDR-TB | Resistance | Literature | 2022 | | GDF procurement improves quality assurance | Supply | Stop TB Partnership | 2023 | ## Validation ![Validation Report](validation_report.png) ## Usage ```python from datasets import load_dataset ds = load_dataset("electricsheepafrica/anti-tb-medicine-quality", "dots_program_public") ``` ## References 1. IntechOpen. Medicines quality in LMICs. 2024. 2. WHO. TB drug quality and DOTS programmes. 2020. 3. Stop TB Partnership/GDF. Quality-assured TB medicines. 2023. ## Citation ```bibtex @dataset{electricsheepafrica_anti_tb_medicine_quality_2025, title={Anti-TB Medicine Quality in Sub-Saharan Africa}, author={Electric Sheep Africa}, year={2025}, publisher={HuggingFace}, url={https://huggingface.co/datasets/electricsheepafrica/anti-tb-medicine-quality} } ``` ## License CC-BY-4.0